Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Clin Cancer Res. 2018 Sep 26;25(1):346–357. doi: 10.1158/1078-0432.CCR-18-1129

Figure 4. DISARM identifies common candidates across cisplatin-resistant solid tumors.

Figure 4.

(A) Plot depicting drugs selected by DISARM as candidates in cisplatin-resistant models from at least two of the nine malignancies analyzed via IC50 data from GDSC. Dot colors and sizes indicate DISARM scores and statistical significance. (B) Map illustrating interrelatedness of targets identified in multiple tumor types in this same analysis.